Please login to the form below
cabozantinib
This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.
NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Ipsen’s Cabometyx (cabozantinib) for patients with differentiated thyroid cancer (DTC) who have either not responded ... Wales. Treatment options
Latest news
-
BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer
Bristol Myers Squibb (BMS), Exelixis and Ipsen have reported positive three-year follow-up results from a phase 3 study of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in advanced renal
-
Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma
The median OS in the overall population was 10.2 months with cabozantinib and eight months with placebo. ... Cabozantinib is an oral tyrosine kinase inhibitor administered daily with routine outpatient monitoring.
-
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
The EC approval for Opdivo plus tyrosine kinase inhibitor Cabometyx (cabozantinib) is based on results from the phase 3 CheckMate-9ER trial, which compared BMS/Ipsen’s regimen to Pfizer’s
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
Bristol Myers Squibb (BMS) and Exelixis also recently revealed new analyses from a phase 3 study of their Opdivo (nivolumab) and Cabometyx (cabozantinib) combination in first-line, advanced RCC.
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
and Exelixis’ tyrosine kinase inhibitor Cabometyx (cabozantinib).
More from news
Approximately 5 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
Charting a course for expansion
Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
-
Deal Watch March 2016
marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib.
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
